These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

486 related items for PubMed ID: 20498843

  • 1. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.
    Hwang JH, Voortman J, Giovannetti E, Steinberg SM, Leon LG, Kim YT, Funel N, Park JK, Kim MA, Kang GH, Kim SW, Del Chiaro M, Peters GJ, Giaccone G.
    PLoS One; 2010 May 14; 5(5):e10630. PubMed ID: 20498843
    [Abstract] [Full Text] [Related]

  • 2. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma.
    Jamieson NB, Morran DC, Morton JP, Ali A, Dickson EJ, Carter CR, Sansom OJ, Evans TR, McKay CJ, Oien KA.
    Clin Cancer Res; 2012 Jan 15; 18(2):534-45. PubMed ID: 22114136
    [Abstract] [Full Text] [Related]

  • 3. High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer.
    Giovannetti E, van der Velde A, Funel N, Vasile E, Perrone V, Leon LG, De Lio N, Avan A, Caponi S, Pollina LE, Gallá V, Sudo H, Falcone A, Campani D, Boggi U, Peters GJ.
    PLoS One; 2012 Jan 15; 7(11):e49145. PubMed ID: 23155457
    [Abstract] [Full Text] [Related]

  • 4. MicroRNA-891b is an independent prognostic factor of pancreatic cancer by targeting Cbl-b to suppress the growth of pancreatic cancer cells.
    Dong Q, Li C, Che X, Qu J, Fan Y, Li X, Li Y, Wang Q, Liu Y, Yang X, Qu X.
    Oncotarget; 2016 Dec 13; 7(50):82338-82353. PubMed ID: 27494897
    [Abstract] [Full Text] [Related]

  • 5. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD, Fu ZQ, Lin Q, Zhou Y, Zhou QB, Li ZH, Tan LP, Chen RF, Liu YM.
    World J Gastroenterol; 2015 Aug 21; 21(31):9348-57. PubMed ID: 26309360
    [Abstract] [Full Text] [Related]

  • 6. MicroRNA-26a-5p is a reliable biomarker in the adjuvant setting for pancreatic ductal adenocarcinoma.
    Takeda Y, Yamada D, Kobayashi S, Sasaki K, Iwagami Y, Tomimaru Y, Noda T, Takahashi H, Asaoka T, Shimizu J, Doki Y, Eguchi H.
    PLoS One; 2024 Aug 21; 19(9):e0310328. PubMed ID: 39288140
    [Abstract] [Full Text] [Related]

  • 7. Postoperative prognosis prediction of pancreatic cancer with seven microRNAs.
    Lee KH, Lee JK, Choi DW, Do IG, Sohn I, Jang KT, Jung SH, Heo JS, Choi SH, Lee KT.
    Pancreas; 2015 Jul 21; 44(5):764-8. PubMed ID: 25906450
    [Abstract] [Full Text] [Related]

  • 8. KIAA1199/CEMIP/HYBID overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
    Koga A, Sato N, Kohi S, Yabuki K, Cheng XB, Hisaoka M, Hirata K.
    Pancreatology; 2017 Jul 21; 17(1):115-122. PubMed ID: 28012880
    [Abstract] [Full Text] [Related]

  • 9. DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma.
    Zhang G, Schetter A, He P, Funamizu N, Gaedcke J, Ghadimi BM, Ried T, Hassan R, Yfantis HG, Lee DH, Lacy C, Maitra A, Hanna N, Alexander HR, Hussain SP.
    PLoS One; 2012 Jul 21; 7(2):e31507. PubMed ID: 22363658
    [Abstract] [Full Text] [Related]

  • 10. Linc00511 acts as a competing endogenous RNA to regulate VEGFA expression through sponging hsa-miR-29b-3p in pancreatic ductal adenocarcinoma.
    Zhao X, Liu Y, Li Z, Zheng S, Wang Z, Li W, Bi Z, Li L, Jiang Y, Luo Y, Lin Q, Fu Z, Rufu C.
    J Cell Mol Med; 2018 Jan 21; 22(1):655-667. PubMed ID: 28984028
    [Abstract] [Full Text] [Related]

  • 11. The prognostic relevance of primary tumor location in patients undergoing resection for pancreatic ductal adenocarcinoma.
    Ling Q, Xu X, Ye P, Xie H, Gao F, Hu Q, Liu Z, Wei X, Röder C, Trauzold A, Kalthoff H, Zheng S.
    Oncotarget; 2017 Feb 28; 8(9):15159-15167. PubMed ID: 28122349
    [Abstract] [Full Text] [Related]

  • 12. Prognostic and predictive value of a five-molecule panel in resected pancreatic ductal adenocarcinoma: A multicentre study.
    Guo JC, Zhang P, Zhou L, You L, Liu QF, Zhang ZG, Sun B, Liang ZY, Lu J, Yuan D, Tan AD, Sun J, Liao Q, Dai MH, Xiao GG, Li S, Zhang TP.
    EBioMedicine; 2020 May 28; 55():102767. PubMed ID: 32361251
    [Abstract] [Full Text] [Related]

  • 13. Usefulness of exosome-encapsulated microRNA-451a as a minimally invasive biomarker for prediction of recurrence and prognosis in pancreatic ductal adenocarcinoma.
    Takahasi K, Iinuma H, Wada K, Minezaki S, Kawamura S, Kainuma M, Ikeda Y, Shibuya M, Miura F, Sano K.
    J Hepatobiliary Pancreat Sci; 2018 Feb 28; 25(2):155-161. PubMed ID: 29130611
    [Abstract] [Full Text] [Related]

  • 14. Stromal microRNA-21 levels predict response to 5-fluorouracil in patients with pancreatic cancer.
    Donahue TR, Nguyen AH, Moughan J, Li L, Tatishchev S, Toste P, Farrell JJ.
    J Surg Oncol; 2014 Dec 28; 110(8):952-9. PubMed ID: 25132574
    [Abstract] [Full Text] [Related]

  • 15. High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
    Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, Yu J, Kayashima T, Hayashi A, Souzaki R, Tajiri T, Onimaru M, Manabe T, Ohtsuka T, Tanaka M.
    Int J Oncol; 2011 Mar 28; 38(3):629-41. PubMed ID: 21243324
    [Abstract] [Full Text] [Related]

  • 16. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.
    Giovannetti E, Funel N, Peters GJ, Del Chiaro M, Erozenci LA, Vasile E, Leon LG, Pollina LE, Groen A, Falcone A, Danesi R, Campani D, Verheul HM, Boggi U.
    Cancer Res; 2010 Jun 01; 70(11):4528-38. PubMed ID: 20460539
    [Abstract] [Full Text] [Related]

  • 17. Analysis of Blood Plasma MicroRNAs to Enable Identification of Patients with Pancreatic Ductal Adenocarcinoma Who Will Benefit from Surgical Resection.
    Gablo N. A, Procházka V, Hlavsa J, Kiss I, Srovnal J, Kala Z, Slabý O.
    Klin Onkol; 2019 Jun 01; 32(Suppl 1):174-176. PubMed ID: 31064193
    [Abstract] [Full Text] [Related]

  • 18. MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions.
    du Rieu MC, Torrisani J, Selves J, Al Saati T, Souque A, Dufresne M, Tsongalis GJ, Suriawinata AA, Carrère N, Buscail L, Cordelier P.
    Clin Chem; 2010 Apr 01; 56(4):603-12. PubMed ID: 20093556
    [Abstract] [Full Text] [Related]

  • 19. Pre-operative Plasma miR-21-5p Is a Sensitive Biomarker and Independent Prognostic Factor in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Resection.
    Karasek P, Gablo N, Hlavsa J, Kiss I, Vychytilova-Faltejskova P, Hermanova M, Kala Z, Slaby O, Prochazka V.
    Cancer Genomics Proteomics; 2018 Apr 01; 15(4):321-327. PubMed ID: 29976637
    [Abstract] [Full Text] [Related]

  • 20. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
    Dimitrakopoulos C, Vrugt B, Flury R, Schraml P, Knippschild U, Wild P, Hoerstrup S, Henne-Bruns D, Wuerl P, Graf R, Breitenstein S, Bond G, Beerenwinkel N, Grochola LF.
    JAMA Surg; 2019 Jun 01; 154(6):e190484. PubMed ID: 30942874
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.